If your eligible patients have questions about AlphaNine SD, answers are just a phone call away. Factors for Health experts are here to talk to your patients one-on-one about benefits, savings options, and more.
Factors for Health offers your patients:
- $0 Copay Assistance Program which may cover eligible patients' out-of-pocket expenses not covered or partially covered by their insurance with no annual monthly limits*†
- Eligible patients include:
- Any patient previously enrolled in the Factors for Health program regardless of when they were enrolled
- Any patient previously treated with AlphaNine SD (coagulation factor IX [human]) prior to April 2023
- Benefits investigation and support services to help patients coordinate with their insurer
- Care Coordination to help your patients gain access to and remain on AlphaNine SD
Your patients can enroll Monday through Friday, 9 AM to 6 PM EST, by calling 844.MY.FACTOR (693.2286).
*Individual claims exceeding $2000 will be reviewed for network eligibility. Claims that are determined to be in-network will be approved and those determined to be out-of-network may be denied by the program administrator.
†To determine the current general out-of-pocket (OOP) maximum limits under the Affordable Care Act visit: https://www.healthcare.gov/glossary/out-of-pocket-maximum-limit/.
Indication
AlphaNine® SD (coagulation factor IX [human]) is indicated for the prevention and control of bleeding in patients with Factor IX deficiency due to hemophilia B.
AlphaNine SD is made from human plasma. Plasma products carry a risk of transmitting infectious agents, including viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.
Incidences of thrombosis or disseminated intravascular coagulation (DIC) have been reported following administration of Factor IX Complex concentrates which contain high amounts of Factor II, VII, and X. AlphaNine SD contains low, nontherapeutic levels of Factor II, VII, and X.
Following administration in surgery patients and individuals with known liver disease, the physician should closely observe the patient for signs and symptoms of potential disseminated intravascular coagulation.
Allergic type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. The administration of plasma preparations may cause allergic reactions, mild chills, nausea or stinging at the infusion site.
Nephrotic syndrome has been reported following attempted immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors and a history of severe allergic reactions to Factor IX.
In order to minimize the possibility of thrombogenic complications, dosing guidelines should be strictly followed.
AlphaNine SD should not be administered at a rate exceeding 10 mL/ minute. Rapid administration may result in vasomotor reactions.
Please see full Prescribing Information for AlphaNine SD.